LabCorp Announces $500 Million Stock Repurchase Program

BURLINGTON, N.C., March 13 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an aggregate of $500,000,000 of its Common

LabCorp is Scheduled to Present at the Cowen and Company 27th Annual Health Care Conference

BURLINGTON, N.C., March 12 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T.

LabCorp(R) Notified by Aetna of Contract Termination

BURLINGTON, N.C., March 1 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world's leading clinical laboratories, today announced that it will no longer be a contracted laboratory provider for Aetna Inc. (NYSE: AET), effective July 1, 2007.

LabCorp is Scheduled to Present at the Susquehanna Financial Group Significant Investment Options in Healthcare Conference

BURLINGTON, N.C., Feb 28, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and

Laboratory Corporation of America(R) Announces 2006 Fourth Quarter and Full Year Results

Fourth Quarter Net Sales Growth of 9.3% Drives Operating Cash Flow of $170.2 million and EPS Increase of 26.6% BURLINGTON, N.C., Feb 15, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the

LabCorp(R) and ARCA Discovery Partner to Commercialize Companion Diagnostic for First Cardiovascular Personalized Medicine

New test identifies genetic variants associated with patient response to new, genetically-targeted heart failure drug Agreement pioneers new model for more efficient development and application of personalized therapies BURLINGTON, N.C., and DENVER, Feb 13, 2007 /PRNewswire-FirstCall via COMTEX

LabCorp Is Scheduled To Present at the UBS Global Healthcare Services Conference

BURLINGTON, N.C., Feb. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T.

LabCorp Is Scheduled To Present at the Wachovia Securities 2007 Healthcare Conference

BURLINGTON, N.C., Jan. 29 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T.

LabCorp Is Scheduled To Present at the 25th Annual JPMorgan Healthcare Conference

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the 25th

Conversion Right Triggered for LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Jan 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon Convertible Subordinated Notes due